Ligand Pharmaceuticals | LGND - Ordinary Share Capital


Ligand Pharmaceuticals reported $19.66M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Agenus USD 266K 30K Mar/2025
Amgen USD 539M 1000K Dec/2025
Anika Therapeutics USD 143K 1000 Mar/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
Baxter International USD 514.28M 168.72M Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Enviri Corporation USD 81.45M 797K Dec/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 214.26M 1.67M Dec/2025
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
Karyopharm Therapeutics USD 13K 0 Sep/2024
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Pacira USD 41.12M 1.85M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 79.05M 377K Dec/2025